Treatment for Community-Acquired Pneumonia in Otherwise Healthy Adults
For an otherwise healthy adult with community-acquired pneumonia managed as an outpatient, treat with a macrolide (azithromycin, clarithromycin, or erythromycin) as first-line therapy. 1
Outpatient Treatment Algorithm
Previously Healthy, No Recent Antibiotics
- Macrolide monotherapy (azithromycin, clarithromycin, or erythromycin) 1
- Alternative: Doxycycline (weaker evidence) 1
This recommendation is based on strong Level I evidence from the 2007 IDSA/ATS guidelines, which remain the most authoritative source for CAP management. The rationale prioritizes coverage of Streptococcus pneumoniae, the most common pathogen in otherwise healthy adults with CAP.
If Recent Antibiotic Use (Within 3 Months) or Comorbidities Present
If the patient has used antibiotics in the past 3 months OR has comorbidities (chronic heart/lung/liver/renal disease, diabetes, alcoholism, malignancies, immunosuppression), escalate therapy to:
- Respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin 750 mg) 1
- OR β-lactam PLUS macrolide: High-dose amoxicillin (1g three times daily) or amoxicillin-clavulanate (2g twice daily) PLUS azithromycin or clarithromycin 1
The concern here is drug-resistant S. pneumoniae (DRSP) and gram-negative pathogens, which require broader coverage.
Duration of Treatment
Treat for a minimum of 3 days if clinical stability is achieved by day 3 2, 3, 4. The 2025 ATS guideline update represents a significant shift from the traditional 5-7 day courses:
- 3 days: If patient achieves clinical stability by day 3 (afebrile, hemodynamically stable, improving symptoms) 3, 4
- 5 days: If stability achieved by day 5 1, 3
- 7 days: For uncomplicated cases not meeting earlier stability criteria 4
Clinical stability means: temperature ≤37.8°C, heart rate ≤100 bpm, respiratory rate ≤24/min, systolic BP ≥90 mmHg, oxygen saturation ≥90%, able to take oral intake, and normal mental status.
Critical Caveats
High Macrolide Resistance Areas
In regions where high-level macrolide-resistant S. pneumoniae exceeds 25% (MIC ≥16 mg/mL), use alternative agents even in previously healthy patients without comorbidities 1. This means defaulting to respiratory fluoroquinolones or β-lactam plus macrolide combinations.
When NOT to Use Macrolide Monotherapy
- Recent antibiotic exposure (past 3 months)
- Any comorbid conditions
- Suspected aspiration (use amoxicillin-clavulanate or clindamycin instead) 5
- Influenza with bacterial superinfection (use β-lactam or respiratory fluoroquinolone) 5
Hospitalized Patients (Non-ICU)
If the patient requires hospitalization but not ICU admission:
β-lactam (cefotaxime, ceftriaxone, or ampicillin) PLUS macrolide 1
- OR respiratory fluoroquinolone monotherapy 1
Both regimens have strong Level I evidence. The combination therapy provides coverage for both typical and atypical pathogens, which is critical for hospitalized patients where mortality risk is higher.
Severe CAP (ICU Admission)
β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) PLUS either azithromycin OR a respiratory fluoroquinolone 1
This combination is mandatory for severe disease because:
- Combination therapy improves mortality in severe pneumococcal pneumonia
- Covers atypical pathogens including Legionella, which has higher mortality if untreated
- Provides broader gram-negative coverage
Special Considerations for Severe CAP:
- Pseudomonas risk factors (structural lung disease, recent hospitalization, recent antibiotics): Use antipseudomonal β-lactam (piperacillin-tazobactam, cefepime, imipenem, meropenem) PLUS ciprofloxacin or levofloxacin 750mg 1
- MRSA risk factors (prior MRSA infection, IV drug use, recent hospitalization): Add vancomycin or linezolid 1
Corticosteroids
Do NOT routinely use corticosteroids for non-severe CAP 2, 3. The 2025 guidelines recommend against routine corticosteroid use based on recent evidence showing no benefit and potential harm in non-severe cases. Consider corticosteroids only in severe CAP requiring ICU admission, but even this is controversial given conflicting trial results 6, 7.
Switch to Oral Therapy
For hospitalized patients, switch from IV to oral antibiotics when hemodynamically stable, clinically improving, afebrile, able to take oral medications, and have normal GI function 1. This typically occurs within the first 2-3 days. Discharge immediately after switch—no need for observation on oral therapy 1.
Common Pitfalls to Avoid
- Don't withhold antibiotics based solely on positive viral testing in patients with radiographic pneumonia, comorbidities, or requiring hospitalization 8, 2, 3
- Don't use fluoroquinolones if patient recently received them (within 3 months)—select alternative class to prevent resistance 1
- Don't treat for longer than necessary—prolonged courses increase resistance and adverse effects without improving outcomes 3, 4
- Don't forget to assess for clinical stability daily—this drives duration decisions 1, 3